AGM Statement

Aortech International PLC 13 July 2000 AGM Statement At the Annual General Meeting of Aortech International held today the Chairman Gordon Wright said: 'As you will have seen from our Annual Report, the year to 31st March saw major strategic and corporate developments in the Aortech Group, which included the extension of our present range of cardio vascular products, and significant technological and regulatory advances in our new products and projects. I can report that the product development and the trials of the new tri-leaf polymer valve are proceeding according to plan, and we continue on course to commence patient trials in the latter half of next year. Our plans for the commercialisation of the TruCOMMS cardiac output monitor are on course, including the marketing of the system in the USA. Our acquisition of ElastoMedic in Australia is working out extremely well, and there is increasing interest in the Elast- Eon material which featured in a number of papers presented to World's major bio-materials conference in Hawaii in May. As you all know, we had a successful fund raising and Open Offer of new shares in February, which was not only well supported by existing shareholders - both institutional investors and individuals - but gave us the opportunity to welcome a number of major new investors to Aortech. I believe that the potential of these world leading technologies: the Elast-Eon material, the new Tri-leaflet heart valve, and the cardiac monitoring system together will ensure AorTech's ongoing strength in the global medical devices and materials sectors in future years.' All resolutions proposed at the AGM were duly passed. 13th July 2000 Enquiries: AorTech International plc Tel: 01698 746699 Eddie McDaid, Managing Director College Hill Tel: 020 7457 2020 Michael Padley
UK 100

Latest directors dealings